Accès à distance ? S'identifier sur le proxy UCLouvain
Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis
Primary tabs
Document type | Article de périodique (Journal article) – Article de recherche |
---|---|
Access type | Accès restreint |
Publication date | 2007 |
Language | Anglais |
Journal information | "Arthritis & Rheumatism" - Vol. 56, no. 12, p. 3928-3939 (2007) |
Peer reviewed | yes |
Publisher | John Wiley & Sons, Inc. |
e-issn | 1529-0131 |
issn | 0004-3591 |
Publication status | Publié |
Affiliations |
UCL
- (SLuc) Service de rhumatologie UCL - MD/MINT - Département de médecine interne |
Links |
- Moreland Larry W., Etanercept Therapy in Rheumatoid Arthritis : A Randomized, Controlled Trial, 10.7326/0003-4819-130-6-199903160-00004
- Klareskog, Lancet, 363, 675 (2004)
- Van der Heijde, Arthritis Rheum, 54, 1063 (2006)
- Maini, Lancet, 354, 1932 (1999)
- Weinblatt, Arthritis Rheum, 48, 35 (2003)
- Weinblatt, N Engl J Med, 340, 253 (1999)
- Bathon, N Engl J Med, 343, 1586 (2000)
- Breedveld, Arthritis Rheum, 54, 26 (2006)
- St.Clair, Arthritis Rheum, 50, 3432 (2004)
- Landewe, Ann Rheum Dis, 61, 479 (2002)
- Twisk, Int J Sports Med, 18, S216 (1997)
- Zeger, Biometrics, 42, 121 (1986)
- Hedeker, Psychol Methods, 2, 64 (1997)
- Hochberg, Arthritis Rheum, 35, 498 (1992)
- Van der Heijde, J Rheumatol, 20, 579 (1993)
- Van Gestel, Arthritis Rheum, 41, 1845 (1998)
- Felson David T., Anderson Jennifer J., Lange Mary L. M., Wells George, LaValley Michael P., Should imporvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent?, 10.1002/1529-0131(199809)41:9<1564::aid-art6>3.0.co;2-m
- Felson, Arthritis Rheum, 38, 727 (1995)
- Felson, Arthritis Rheum, 36, 729 (1993)
- Van der Heijde, Lancet, 1, 1036 (1989)
- Landewe, Arthritis Rheum, 50, 699 (2004)
- Van der Heijde D, Klareskog L, Baker P, Wajdula J, Fatenejad S. Etanercept combined with methotrexate is well tolerated for 3 years: results from the trial of etanercept and methotrexate with radiographic and patient outcomes (TEMPO). Poster number SAT0196. Presented at the Annual European Congress of Rheumatology, June 21-24, 2006, Amsterdam, The Netherlands.
- Fries, Arthritis Rheum, 23, 137 (1980)
- Van der Heijde, Ann Rheum Dis, 64, 1582 (2005)
- Landewe, Arthritis Rheum, 54, 3119 (2006)
Bibliographic reference | Van Der Heijde, D. ; Klareskog, L. ; Landewé, R. ; Bruyn, G.A.W. ; Cantagrel, A. ; et. al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. In: Arthritis & Rheumatism, Vol. 56, no. 12, p. 3928-3939 (2007) |
---|---|
Permanent URL | http://hdl.handle.net/2078.1/164706 |